Introduction
Reduced tetrahydrofolates (THF) serve as cofactors that carry one-carbon moieties for 1) the synthesis of de novo purines and thymidylate (dTMP) and 2) remethylation of homocysteine to methionine ( Figure 1 ). The anti-folate methotrexate (MTX) and its active polyglutamate forms inhibit RNA and DNA synthesis in cells by inhibiting dihydrofolate reductase (DHFR) and thymidylate synthase (TS), respectively, two crucial enzymes in pyrimidine synthesis and folate recirculation ( Figure 1 ). MTX is an important chemotherapeutic drug in the treatment of acute lymphoblastic leukemia (ALL) and other malignancies. Recent clinical and in-vitro studies indicate that common polymorphisms in genes coding for enzymes involved in folate metabolism affect the sensitivity of patients to folate-based chemotherapeutic drugs such as MTX. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] This may be a direct effect or indirect due to shifts in intracellular folate distribution. 9, 11 We investigated whether common polymorphisms in folate-related genes influence (ex-vivo) MTX sensitivity.
Methods
From newly diagnosed West-European pediatric ALL patients, peripheral blood or bone marrow mononuclear cells were isolated with Ficoll Isopaque (>80% leukemic cell enrichment) and MTX sensitivity was previously measured with the in-situ thymidylate synthase inhibition assay (TSI). in an earlier small pilot-study (n=6) greater MTX sensitivity was observed in the two MTHFR 677TT
patients. 6 The MTHFR 677T1298A haplotype or the MTHFD1 1958A variant, in interaction with the TS 3R repeat, resulted in a decreased event-and disease-free survival in pediatric ALL patients treated with MTX. 10 Sohn et al. 9 transfected human colon and breast cancer cells with either wild-type or mutant 677T human MTHFR cDNA. Only mutant cells had decreased MTHFR activity, changed intracellular folate distribution, increased TS activity and decreased chemosensitivity towards MTX.
Our study with clinical samples of childhood ALL could not confirm the influence of the MTHFR 677C>T polymorphism on ex-vivo MTX sensitivity although a trend towards decreased sensitivity was observed. Some of the discrepancies might be explained by the different conditions used for the invitro assays. In our assay, high folate is present in the culture medium possibly counteracting changed folate redistribution due to polymorphisms in folate genes. The clinical results are possibly explained by changed folate distribution. We have no explanation why only the heterozygous MTHFR 1298AC variant showed decreased MTX sensitivity whereas the homozygous (CC) variant did not.
Also, in other diseases in which MTX is being used, genetic polymorphisms play a role.
MTHFR 1298A>C and not MTHFR 677C>T modulated the efficacy of MTX treatment in rheumatoid arthritis patients whereas MTHFR 677C>T was related to toxicity. 3, 5 Both TS 2R/3R 7, 21 and RFC 80G>A 21 polymorphisms influenced efficacy and not toxicity of low-dose MTX therapy in patients with rheumatoid arthritis while both MTHFR polymorphisms showed no effect. 7 Our study is the first to report on the MTRR 66A>G and SHMT1 1420C>T polymorphisms as pharmacogenetic determinants of MTX treatment efficacy. Further studies are warranted to evaluate the effect of these polymorphisms on enzyme activity and on intracellular folate redistribution.
However, increased risk of neural tube defect pregnancy outcome and cardiovascular disease have In conclusion, we show that the common polymorphisms in the folate-related genes MTHFR, MTRR and SHMT1 are related to in-vitro MTX sensitivity in pediatric ALL patients. To date, the MTX dose applied mostly is based on the body surface area while the patient's cellular folate status or pharmacogenetic background 25 is not yet routinely taken into account. Identifying predictors of MTX sensitivity may lead to the development of individualized treatment strategies with improved efficacy and reduced toxicity. In some countries but not the Netherlands, the TPMT polymorphism is used to dose-adjust the initial does of 6-mercaptopurine. We feel that in a similar way, polymorphisms in folate-related genes such as MTRR could be used to adjust the initial (not maintenance) MTX dose once firmly is established that these polymorphisms influence efficacy and/or toxicity. In 500 healthy
Caucasians, we established high allele frequencies of MTRR 66A>G (55%), MTHFR 1298A>C (31%) and SHMT1 1420C>T (32%). Athough ethnic and geographic variations exist in these polymorphisms, high allele frequencies have also been reported in other ethnic groups and thus, they may significantly contribute to sensitivity and toxicity associated with MTX treatment. 
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